Literature DB >> 2846771

Frequent integration of hepatitis B virus DNA in noncancerous liver tissue from hepatocellular carcinoma patients.

Y Tanaka1, M Esumi, T Shikata.   

Abstract

To investigate the relationship between hepatocarcinogenesis and integration of hepatitis B virus (HBV) DNA in the cellular DNA of the liver, we studied the integration of HBV DNA in various noncancerous regions of the liver from 31 patients using Southern blot analysis. Of 13 patients without hepatocellular carcinoma (HCC), 4 had heterogeneously integrated HBV DNA. Of the latter four patients, two had chronic liver disease, and two had nonspecific histological changes. In contrast, integration of HBV DNA was found in noncancerous tissue from 11 of 18 patients with HCC. In eight patients, homogeneous integration was found in noncancerous tissue, and restriction fragments of integrated HBV DNA were different from those found in cancerous tissue. Moreover, integration of HBV DNA was found in all portions examined from the same liver, and homogeneously integrated HBV DNA showed different restriction patterns in different areas. These results suggest that integration of HBV DNA may occur in heterogeneous sites of cellular DNA before hepatocarcinogenesis. Subsequently, multi-focal clonal populations develop from these hepatocytes, especially frequently in the case of HCC. Integrated HBV DNA may play an important role in the clonal growth of hepatocytes, although the development of HCC requires additional factors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2846771     DOI: 10.1002/jmv.1890260103

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  The cytoplasmic HBVDNA implication: HBV replication or non-replicative status.

Authors:  Y Y Zhang; P Yan; Z Q Yu; Y K Wang; L J Hao
Journal:  J Tongji Med Univ       Date:  1990

Review 2.  Moving Towards Therapy in SCA1: Insights from Molecular Mechanisms, Identification of Novel Targets, and Planning for Human Trials.

Authors:  Sharan R Srinivasan; Vikram G Shakkottai
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

3.  Clonal state of human hepatocellular carcinoma and non-tumorous hepatocytes.

Authors:  M Esumi; Y Tanaka; S Tozuka; T Shikata
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma.

Authors:  Chau-Ting Yeh; Hui-Chin Chen; Chang-Mu Sung; Cheng-Lung Hsu; Chen-Chun Lin; Kuang-Tse Pan; Jeng-Hwei Tseng; Chien-Fu Hung
Journal:  BMC Cancer       Date:  2011-03-31       Impact factor: 4.430

5.  Liver cell transformation in chronic HBV infection.

Authors:  Shirine Benhenda; Delphine Cougot; Christine Neuveut; Marie Annick Buendia
Journal:  Viruses       Date:  2009-10-30       Impact factor: 5.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.